Teprotumumab Granted Priority Review From FDA for Active Thyroid Eye Disease
The FDA has accepted for priority review the Biologics License Application (BLA) for teprotumumab (Horizon Therapeutics) for the treatment of active thyroid eye disease.
All articles by Diana Ernst, RPh
CDC: Strategies to Reduce Prescription Drug Costs in Diabetes
Results showed that those with private insurance were more likely than those with Medicaid to request a lower-cost alternative.
Does Osteoporosis Treatment Reduce Overall Mortality in Addition to Fracture Risk?
The meta-analysis included 101,642 patients with osteoporosis.
Do US Adults Use More Prescription Drugs Than Canadians?
Prescription drug use appears to be similar in the US and Canada, according to a new data brief from the Centers for Disease Control and Prevention (CDC).
Evinacumab Effective in Homozygous Familial Hypercholesterolemia Trial
Results from a phase 3 trial evaluating the efficacy of evinacumab (Regeneron) in the treatment of patients with homozygous familial hypercholesterolemia (HoFH) showed that the investigational angiopoietin-like 3 (ANGPTL3) antibody reduced low-density lipoprotein (LDL) cholesterol by 49%.
Next post in Type 1 Diabetes
